SmithKline Beecham/Coulter Pharmaceuticals Bexxar
Executive Summary
Companies will jointly commercialize Coulter's cancer therapy candidate iodine I 131 tositumomab. Coulter will receive $41.5 mil. upfront, including the purchase of $7.3 mil. in equity. SB and Coulter will jointly market Bexxar in the U.S., and SB will market the compound outside the U.S., excluding Japan. Coulter has completed a Phase III study of Bexxar in non-Hodgkin's lymphoma and anticipates completing an NDA in second quarter 1999